Clinigen Group PLC - Staffordshire-based pharmaceuticals and services provider - Signs an exclusive agreement to manage the supply and distribution of Orphelia Pharma's Kigabeq into unlicensed markets. Kigabeq was granted a European Paediatric Use Marketing Authorisation in 2018 and is currently used for the treatment of infantile spasms and pharmaco-resistant focal-onset seizures.
Under the terms of the agreement, Clinigen will provide Kigabeq in markets where it is not commercially available. Clinigen will manage all elements of the supply covering all global territories except for the US, China, the EU, UK and Bangladesh.
Chief Operating Officer Sam Herbert comments: "We are pleased to be partnering with Orphelia Pharma and to be supplying Kigabeq through our product lifecycle platform.
"This agreement will offer healthcare professionals another option to treat difficult-to-manage types of epilepsy. This is a great example of how Clinigen's lifecycle platform can help patients gain access to medicines which are not otherwise available."
Current stock price: 587.50 pence
Year-to-date change: down 13%
By Will Paige; willpaige@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
